{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-018312","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.567444+00:00","generated_at":"2026-05-16T01:16:14.630009+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"confidence":"high","headline":"Zura Bio appoints Eisner and Nirula to board; Graham resigns","bullets":["Neil Graham resigned from Zura's board effective Feb 21, 2026; departure not due to any disagreement.","Mark Eisner (Vir Bio CMO) and Ajay Nirula (Recludix Pharma EVP R&D, former Lilly exec) appointed as directors.","Each new director receives $40k annual cash retainer and initial option for up to 51,000 shares (or $200k value).","Board changes come as Zura advances Phase 2 tibulizumab trials in hidradenitis suppurativa and systemic sclerosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-018312","json":"https://secwatch.observer/filing/0001104659-26-018312.json","markdown":"https://secwatch.observer/filing/0001104659-26-018312.md","text":"https://secwatch.observer/filing/0001104659-26-018312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926018312/0001104659-26-018312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926018312/tm267035d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:16:14.630009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}